Generation Bio Past Earnings Performance
Past criteria checks 0/6
Generation Bio's earnings have been declining at an average annual rate of -18.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 141.7% per year.
Key information
-18.7%
Earnings growth rate
44.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 141.7% |
| Return on equity | -137.3% |
| Net Margin | -1,202.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10Revenue & Expenses Breakdown
How Generation Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 13 | -158 | 58 | 0 |
| 31 Mar 24 | 10 | -169 | 62 | 0 |
| 31 Dec 23 | 6 | -127 | 65 | 0 |
| 30 Sep 23 | 3 | -124 | 65 | 0 |
| 30 Jun 23 | 1 | -127 | 65 | 0 |
| 31 Mar 23 | 0 | -134 | 68 | 0 |
| 31 Dec 22 | 0 | -137 | 67 | 0 |
| 30 Sep 22 | 0 | -135 | 62 | -56 |
| 30 Jun 22 | 0 | -136 | 59 | -37 |
| 31 Mar 22 | 0 | -129 | 50 | -17 |
| 31 Dec 21 | 0 | -119 | 44 | 0 |
| 30 Sep 21 | 0 | -112 | 49 | 63 |
| 30 Jun 21 | 0 | -101 | 43 | 59 |
| 31 Mar 21 | 0 | -88 | 34 | 55 |
| 31 Dec 20 | 0 | -81 | 32 | 0 |
| 30 Sep 20 | 0 | -72 | 21 | 52 |
| 30 Jun 20 | 0 | -68 | 21 | 47 |
| 31 Mar 20 | 0 | -65 | 24 | 42 |
| 31 Dec 19 | 0 | -61 | 22 | 41 |
| 31 Dec 18 | 0 | -36 | 12 | 25 |
Quality Earnings: GBIO is currently unprofitable.
Growing Profit Margin: GBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GBIO is unprofitable, and losses have increased over the past 5 years at a rate of 18.7% per year.
Accelerating Growth: Unable to compare GBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: GBIO has a negative Return on Equity (-137.28%), as it is currently unprofitable.